Conjugated To Proteinaceous Toxin Or Fragment Thereof (e.g., Conjugated To Diphtheria Toxin, Pseudomonas Exotoxin, Ricin, Gelonin, Abrin, Etc.) Patents (Class 424/183.1)
-
Publication number: 20080138276Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: November 13, 2007Publication date: June 12, 2008Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Publication number: 20080131365Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: November 13, 2007Publication date: June 5, 2008Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Patent number: 7378091Abstract: The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity of CA IX, in particular, tumors such as colorectal cancer, renal cell carcinoma (RCC), cervical and other cancers of epithelial origin.Type: GrantFiled: December 2, 2002Date of Patent: May 27, 2008Assignee: Amgen Fremont Inc.Inventors: Jean Gudas, Ian Foltz, Masahisa Handa, Michael L. Gallo
-
Publication number: 20080102027Abstract: The present invention relates to the diagnosis and treatment of B-cell disorders such as multiple myeloma (MM). In particular, the present invention relates to the treatment of B-cell disorders using ligands which bind to free lambda light chains expressed on the surface of lymphoid cancer cells.Type: ApplicationFiled: February 28, 2005Publication date: May 1, 2008Applicant: PACMAB LIMITEDInventors: Rosanne D. Dunn, Darren R. Jones, Parisa Asvadi, Robert L. Raison, Andrew T. Hutchinson
-
Patent number: 7361342Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: January 20, 2004Date of Patent: April 22, 2008Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7361343Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.Type: GrantFiled: March 26, 2004Date of Patent: April 22, 2008Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay, Luis A. G. da Cruz
-
Publication number: 20080025913Abstract: Antibodies to DC-SIGN are disclosed which are capable of modulating the interaction of dendritic cells and T cells. In some embodiments, the antibodies inhibit the interaction of dendritic cells and T cells. In other embodiments, the antibodies are combined with peptides which are internalized in dendritic cells and presented to T cells, thereby generating an immune response to the peptide. The antibodies of the present disclosure may, in some embodiments, be useful in blocking viral binding, infection, and transmission.Type: ApplicationFiled: December 15, 2004Publication date: January 31, 2008Inventors: Katherine S. Bowdish, Anke Kretz-Rommel
-
Patent number: 7319139Abstract: Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.Type: GrantFiled: January 29, 2002Date of Patent: January 15, 2008Assignee: Biogen Idec, Inc.Inventors: Gary R Braslawsky, Nabil Hanna, Paul Chinn, Kandasamy Hariharan
-
Patent number: 7314632Abstract: This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.Type: GrantFiled: July 10, 1998Date of Patent: January 1, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventor: David J. Fitzgerald
-
Patent number: 7307154Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.Type: GrantFiled: July 8, 2003Date of Patent: December 11, 2007Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
-
Patent number: 7288255Abstract: The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.Type: GrantFiled: May 11, 2000Date of Patent: October 30, 2007Assignee: Yale UniversityInventors: Warren D. Shlomchik, Mark Jay Shlomchik, Stephen G. Emerson
-
Patent number: 7285269Abstract: Antibodies directed to the antigen TNF? and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: December 2, 2003Date of Patent: October 23, 2007Assignee: Amgen Fremont, Inc.Inventors: John S. Babcook, Jaspal S. Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina Liang, Yen-Wah Lee, Kathy Manchulenko, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su
-
Patent number: 7282476Abstract: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.Type: GrantFiled: August 23, 2002Date of Patent: October 16, 2007Assignees: University of Victoria Innovation and Development Corporation, Johns Hopkins UniversityInventors: Samuel R. Denmeade, John T. Isaacs, James Thomas Buckley
-
Patent number: 7264809Abstract: The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.Type: GrantFiled: October 13, 1999Date of Patent: September 4, 2007Assignees: Immunex Corporation, Cornell Research Foundation, Inc.Inventors: Richard B. Gayle, III, Aaron J. Marcus, Charles R. Maliszewski
-
Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
Patent number: 7226601Abstract: A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a V? of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.Type: GrantFiled: June 7, 1995Date of Patent: June 5, 2007Assignee: Active Biotech ABInventors: Lars Abrahmsen, Per Bjork, Mikael Dohlsten, Terje Kalland -
Patent number: 7227002Abstract: The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.Type: GrantFiled: April 14, 1998Date of Patent: June 5, 2007Assignee: Micromet AGInventors: Peter Kufer, Tobias Raum
-
Patent number: 7226596Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.Type: GrantFiled: August 22, 2002Date of Patent: June 5, 2007Assignee: Genentech, Inc.Inventors: Sarah C. Bodary, Karen L. Fisher
-
Patent number: 7223397Abstract: The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.Type: GrantFiled: January 7, 1999Date of Patent: May 29, 2007Assignee: Research Development FoundationInventors: Michael Rosenblum, Kapil Mehta
-
Patent number: 7189825Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: July 15, 2004Date of Patent: March 13, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7189816Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23–33 (CDR1), 49–55 (CDR2), 88–98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158–162 (CDR1), 177–193 (CDR2, 226–238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.Type: GrantFiled: October 26, 2000Date of Patent: March 13, 2007Assignee: Active Biotech ABInventors: Thomas Brodin, Pia J. Karlström, Lennart G. Ohlsson, Jesper M. Tordsson, Philip P. Kearney, Bo H. K. Nilson
-
Patent number: 7186808Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: July 15, 2004Date of Patent: March 6, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7183388Abstract: This invention provides novel antibodies that specifically bind to the cancer antigen MUC-1. The antibodies are useful targeting moieties for specifically directing imaging agents and various therapeutic moieties to a cancer.Type: GrantFiled: May 9, 2003Date of Patent: February 27, 2007Assignee: The Regents of the University of CaliforniaInventors: Sally Joan Denardo, Michelle Denise Winthrop, Gerald Louis Denardo, Cheng-Yi Xiong
-
Patent number: 7175846Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: August 3, 2006Date of Patent: February 13, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7157087Abstract: A method for enhancing intracellular delivery of effector molecules is provided. The method involves modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target specifically recognized by the antibody.Type: GrantFiled: May 28, 2003Date of Patent: January 2, 2007Assignee: Trustees of the University of PennsylvaniaInventors: Vladimir R. Muzykantov, Steve M. Albelda
-
Patent number: 7147849Abstract: A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes.Type: GrantFiled: May 5, 2003Date of Patent: December 12, 2006Assignee: Bitop AGInventor: Stefan Barth
-
Patent number: 7135185Abstract: Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a pharmaceutically acceptable carrier, such as a diphtheria toxoid.Type: GrantFiled: May 9, 1995Date of Patent: November 14, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 7129332Abstract: The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions (“CDRs”) of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.Type: GrantFiled: February 23, 2001Date of Patent: October 31, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ira Pastan, Richard Beers, Partha S. Chowdhury, Darell Bigner
-
Patent number: 7125554Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.Type: GrantFiled: July 6, 2001Date of Patent: October 24, 2006Assignee: Active Biotech ABInventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
-
Patent number: 7125541Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: December 14, 2000Date of Patent: October 24, 2006Assignee: The University of Texas System Board of RegentsInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 7125553Abstract: Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease.Type: GrantFiled: August 26, 1999Date of Patent: October 24, 2006Assignees: The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention, The UAB Research FoundationInventors: David M. Neville, Stuart Knechtle, Judith M. Thomas
-
Patent number: 7115716Abstract: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.Type: GrantFiled: November 19, 2002Date of Patent: October 3, 2006Assignee: Eli Lilly and CompanyInventor: Jeffry D. Watkins
-
Patent number: 7112317Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: February 27, 2003Date of Patent: September 26, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 7105159Abstract: This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibodies.Type: GrantFiled: June 6, 1995Date of Patent: September 12, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 7105149Abstract: This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins, having the amino acid sequences set forth in any of FIGS. 18A, 18B-1–18B-3, 18C-1–18C-2, 18D-1–18D-2 or 18E-1–18E-2. Oligonucleotides of the isolated nucleic acid molecules are provided. Antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins are also provided, as are pharmaceutical compositions comprising such antibodies or oligonucleotides. Methods for detecting a B cell malignancy in a sample from a subject; diagnosing B cell malignancy in a sample from a subject; detecting human IRTA protein in a sample; and treating a subject having a B cell cancer are also provided.Type: GrantFiled: November 28, 2000Date of Patent: September 12, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventor: Riccardo Dalla-Favera
-
Patent number: 7097835Abstract: The present invention provides immunoselective targeting agents that bind to transporters that are transiently accessible on the surface of neuronal cells, and that deliver compounds selectively to such cells. The invention provides methods of selectively killing, as well as methods of selectively promoting survival of, a neuronal cell.Type: GrantFiled: July 17, 2002Date of Patent: August 29, 2006Assignee: The Regents of the University of CaliforniaInventors: Leo M Chalupa, Emine Gunhan, Prabhakara V. Choudary
-
Patent number: 7097839Abstract: Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed.Type: GrantFiled: June 6, 1995Date of Patent: August 29, 2006Assignee: Thomas Jefferson UniversityInventor: Scott A. Waldman
-
Patent number: 7094404Abstract: The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.Type: GrantFiled: June 7, 1995Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Thomas A. Waldmann
-
Patent number: 7052702Abstract: A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particularly chronic pain.Type: GrantFiled: October 7, 1998Date of Patent: May 30, 2006Assignees: Health Protection Agency, Ipsen LimitedInventors: Michael John Duggan, John Andrew Chaddock
-
Patent number: 7041293Abstract: The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.Type: GrantFiled: June 23, 1998Date of Patent: May 9, 2006Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
-
Patent number: 7029899Abstract: This invention provides RNase A superfamily polypeptides with modified amino terminal which can be used to selectively kill target Kaposi's sarcoma cells, neoplastic endothelial cells, and non-neoplastic endothelial cells. In certain embodiments of the invention, the amino terminal modification consists of an addition of 4 amino acid sequence consisting of the SLHV sequence at position ?4 to ?1 to the eosinophil derived neurotoxin protein. The amino terminal addition is capable of directing the claimed RNase A superfamily polypeptides to proliferating endothelial cells, such as Kaposi's sarcoma cells, and selectively killing these cells.Type: GrantFiled: November 1, 1999Date of Patent: April 18, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Susanna M. Rybak, Dianne L. Newton
-
Patent number: 7018633Abstract: Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles.Type: GrantFiled: July 10, 2003Date of Patent: March 28, 2006Assignee: Battelle Energy Alliance, LLCInventors: William K. Keener, Thomas E. Ward
-
Patent number: 7009040Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: January 21, 2003Date of Patent: March 7, 2006Assignee: Arius Research, Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7001994Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose 6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.Type: GrantFiled: January 17, 2002Date of Patent: February 21, 2006Assignee: Genzyme CorporationInventor: Yunxiang Zhu
-
Patent number: 6986891Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to surface antigen expressed on multiple myeloma cells and on ovarian cancer cells.Type: GrantFiled: November 28, 2001Date of Patent: January 17, 2006Assignee: Molecular Discoveries, L.L.C.Inventor: Cohava Gelber
-
Patent number: 6969519Abstract: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.Type: GrantFiled: September 25, 2001Date of Patent: November 29, 2005Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Kevin P. Baker
-
Patent number: 6962694Abstract: A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a “free” superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1) (T)x(Sag)y(IM)z; a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respectively, in a given conjugate molecule, with the provision that y>0 and also one or both of x and z>0. The superantigen conjugate is preferably a triple fusion protein.Type: GrantFiled: July 21, 1998Date of Patent: November 8, 2005Assignee: Active Biotech AGInventors: Morten Soegaard, Lars Abrahmsen, Peter Lando, Goran Forsberg, Terje Kalland, Mikael Dohlsten
-
Patent number: 6962702Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: April 3, 2001Date of Patent: November 8, 2005Assignee: Immunomedics Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 6962703Abstract: The invention relates to an agent specific for peripheral sensory afferents. The agent may inhibit the transmission of signals between a primary sensory afferent and a projection neutron by controlling the release of at least one neurotransmitter or neuromodulator from the primary sensory afferent. The agent may be used in or as a pharmaceutical for the treatment of pain, particularly chronic pain.Type: GrantFiled: May 20, 2002Date of Patent: November 8, 2005Assignees: Ipsen Limited, Health Protection AgencyInventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 6953568Abstract: Endothelial protein C receptor (EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Molecules which bind to EPCR can be carried from the plasma membrane surface to the nucleus. These molecules include antibodies to EPCR and activated protein C. Protein C, which also binds to EPCR, can be internalized by endothelial cells, but does not enter the nucleus. Thus, EPCR translocation from the plasma membrane to the nucleus provides a means of delivering nucleic acid such as DNA, proteins such as transcription factors, diagnostic agents or other types of drugs to the nucleus of endothelial cells, particularly those on large blood vessels. Conjugates of the materials to be delivered to the nucleus can be formed by ionic or covalent coupling. For example, proteins, including fusion proteins, can be directly conjugated to an anti-EPCR monoclonal antibody.Type: GrantFiled: August 25, 1998Date of Patent: October 11, 2005Assignee: Oklahoma Medical Research FoundationInventors: Charles T. Esmon, Jun Xu
-
Patent number: 6946129Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: June 8, 1999Date of Patent: September 20, 2005Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.